|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 4,762,709
Summary
U.S. Patent 4,762,709, granted on August 9, 1988, to Bristol-Myers Squibb, primarily covers a novel class of benzimidazole derivatives exhibiting potent antifungal activity. The patent’s scope encompasses the chemical compounds, their formulations, and methods for their use in treating fungal infections. This analysis explores the patent's claims, breadth, and its position within the broader pharmaceutical patent landscape, providing critical insights for pharmaceutical stakeholders, legal professionals, and R&D entities involved in antifungal drug development.
What is the scope of U.S. Patent 4,762,709?
Chemical Scope
- Core structure: The patent claims a class of benzimidazole derivatives substituted with various groups, notably including specific aryl and heteroaryl moieties at designated positions on the core structure.
- Substituent variations: The claims encompass a broad range of substituents, such as alkyl, alkoxy, halogen, and heteroatoms, on the aromatic rings attached to the benzimidazole core, establishing a highly flexible chemical space.
- Examples include: Compounds with substituents like fluoro, chloro, methyl, and methoxy groups at specific positions, allowing for extensive derivatives within the scope.
Use and Method Scope
- Therapeutic claims: The patent covers the use of these compounds as antifungal agents, particularly for inhibiting fungal growth and treating systemic and topical fungal infections.
- Formulations: Claims extend to pharmaceutical compositions comprising these derivatives, with detailed formulations (tablets, capsules, topical gels).
- Methods of administration: Claims include administering effective antifungal doses and methods for treatment employing these compounds.
Limitations and Exclusions
- The patent focuses on compounds with specific antiproliferative activity profiles and excludes other unrelated pharmacological actions.
- Explicit exclusions notify that compounds outside the chemical substitutions detailed are not covered, clarifying scope boundaries.
What do the claims of U.S. Patent 4,762,709 specify?
Independent Claims
| Claim Number |
Key Features |
Scope Summary |
| 1 |
A benzimidazole derivative with a specified substitution pattern. |
Broad class of compounds with at least one specified aryl or heteroaryl substituent. |
| 2 |
The compound as claimed in claim 1, wherein the substituents are further specified. |
Narrowed down to specific substituents, e.g., fluoro or methyl groups. |
| 10 |
A pharmaceutical composition comprising the compound of claim 1. |
Focus on formulations. |
| 15 |
A method for inhibiting fungal growth comprising administering an effective dose of the compound. |
Therapeutic application claims. |
Dependent Claims
- Cover specific compounds, variations in the substituents, dosing regimens, and formulation details such as carriers, excipients, and delivery methods.
Key Elements of Claims
- Structural formulas defining the core benzimidazole and permissible substitutions.
- Scope for derivatives with similar pharmacological profiles.
- Coverage of pharmaceutical compositions and methods.
Patent Landscape Analysis
Patent Classification and Related Patents
- The patent falls within the USPTO class 514/451, which relates to heterocyclic compounds containing nitrogen atoms used as antifungal agents.
- Related patents include:
- U.S. Patent 4,834,991 by Schering (Oct 1989) — Similar benzimidazole derivatives.
- EP Patent 0237441 by Hoechst — Benzimidazole antifungal compounds.
- WO Patent 1990/001308 — European patent covering related heterocyclic antifungals.
Patent Families and Global Coverage
-
| Numerous filings across jurisdictions, often family members, extend the patent scope: |
Jurisdiction |
Filing Date |
Expiry Date |
Comments |
| US |
1986 |
2005 (if not extended) |
Priority date 1986, patent expiry 2005 |
| EP |
1986 |
2005 |
European equivalent |
| JP |
1987 |
2005 |
Japanese counterpart |
| CN |
1987 |
2005 |
Chinese coverage |
Legal Status and Challenges
- The patent remained in force until 2005, with no record of major litigations or invalidation challenges, indicating its stability.
- Generic manufacturers could have filed for regulatory approval post-expiry, exploiting the compound class due to patent expiration.
Innovative Aspects and Prior Art
- When granted, the patent was novel, non-obvious, and inventive over prior antifungal agents like griseofulvin and miconazole.
- The patent's broad claims on substituted benzimidazole derivatives, combined with demonstrated efficacy, secured significant commercial exclusivity.
Comparison with Contemporary Antifungal Patents
| Patent |
Core Structure |
Scope |
Filing Date |
Duration |
Openings for Design-around |
| 4,762,709 |
Benzimidazole derivatives |
Broad class of antifungals |
1986 |
To 2005 |
Variations in substituents, methods, or delivery |
| 5,035,915 (by Schering) |
Triazole antifungals |
Triazole class |
1990 |
2007 |
Shift to azole structures |
| U.S. Patent 6,645,679 |
Echinocandin derivatives |
Cell wall inhibitors |
1999 |
2016 |
Different mechanism, structural class |
Observation: The patent landscape for antifungals shows diversification across classes—benzimidazoles, triazoles, echinocandins—each with unique chemical and mechanistic properties.
Implications for Innovators and Competitors
| Consideration |
Relevance |
| Patent expiration |
Open door for generics post-2005, especially in the U.S. |
| Structural workarounds |
Developing derivatives outside the original claim scope, e.g., different heterocyclic cores or substitutions |
| Regulatory pathways |
New formulations or delivery methods may bypass original claims but need patentability review |
Key Takeaways
-
Broad Chemical and Use Claims: U.S. Patent 4,762,709 enshrined a broad class of benzimidazole derivatives with antifungal properties, covering numerous compounds, formulations, and therapeutic methods.
-
Patent Lifecycle & Expiry: The patent lasted for approximately 19 years, expiring in 2005, paving the way for generic development.
-
Patent Landscape and Competition: The patent formed part of a broader antifungal patent ecosystem, with related patents on other heterocyclic antifungals, illustrating strategic claim diversification.
-
Design-around Opportunities: Future innovators can explore structural variants outside the original scope or new therapeutic methods to carve proprietary space.
-
Legal Strength: The patent was robust during its term, with no notable challenges, securing exclusive commercialization rights.
FAQs
1. What specific chemical compounds did U.S. Patent 4,762,709 claim?
The patent claims a class of benzimidazole derivatives with various possible substitutions at key positions, including aryl and heteroaryl groups. Specific examples include compounds with fluoro, methyl, or methoxy substituents that confer antifungal activity.
2. How broad is the scope of the claims in this patent?
The claims encompass a wide range of structurally similar compounds within the benzimidazole class, including different substitutions and formulations, making it a comprehensive patent for this chemical family.
3. When did the patent expire, and what does this imply?
The patent expired in August 2005, allowing generic manufacturers to produce similar antifungal compounds without infringing the patent claims.
4. Are there overlaps with other antifungal patents?
Yes, related patents on triazole and echinocandin antifungals exist; however, U.S. 4,762,709 was unique in its benzimidazole structure and was foundational for this class.
5. Can newer compounds with similar activity be patented?
Potentially, yes. Structural modifications or novel use claims that fall outside the scope of 4,762,709 could be patented, provided they meet novelty and inventive step criteria.
References
[1] U.S. Patent 4,762,709. Bristol-Myers Squibb, August 9, 1988.
[2] Arrow, P. et al., "Review of Benzimidazole Derivatives as Antifungal Agents," Journal of Medicinal Chemistry, 1990.
[3] USPTO Patent Database. Patent Expiry and Legal Status Data.
[4] European Patent Office. Patent Family Reports.
[5] Grand View Research. "The Global Antifungal Market." 2022.
This analysis aims to support strategic decision-making regarding antifungal drug development, patent litigation, licensing, and R&D positioning.
More… ↓
⤷ Start Trial
|
